XML 56 R37.htm IDEA: XBRL DOCUMENT v3.20.4
The Company (Details)
12 Months Ended
Dec. 31, 2020
USD ($)
segment
product
Oct. 28, 2020
USD ($)
Dec. 31, 2019
USD ($)
Sep. 30, 2019
USD ($)
Organization, Consolidation and Presentation of Financial Statements [Line Items]        
Number of operating segments | segment 1      
Number U.S. FDA approved products | product 2      
Collaborative Arrangement        
Organization, Consolidation and Presentation of Financial Statements [Line Items]        
Upfront payment receivable   $ 50,000,000.0    
Convertible Senior Notes Due 2024 | Convertible debt        
Organization, Consolidation and Presentation of Financial Statements [Line Items]        
Principal amount $ 316,250,000   $ 316,250,000 $ 316,250,000
Debt instrument, interest rate percentage       1.50%